{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:55:41Z","timestamp":1789757741166,"version":"4.0.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.rmr.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T06:58:18Z","timestamp":1519369098000},"page":"171-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aspergillose pulmonaire invasive"],"prefix":"10.1016","volume":"35","author":[{"given":"E.","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jeanne-Leroyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Servant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-Y.","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2018.01.002_bib0590","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.rmr.2018.01.002_bib0595","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0600","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0605","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/tid.12362","article-title":"Invasive mold infections in lung and heart-lung transplant recipients: Stanford University experience","volume":"17","author":"Vazquez","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0610","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CMR.18.1.44-69.2005","article-title":"Aspergillus infections in transplant recipients","volume":"18","author":"Singh","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.rmr.2018.01.002_bib0615","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0620","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e31825f95b9","article-title":"Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey","volume":"91","author":"Chandesris","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rmr.2018.01.002_bib0625","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/505870","article-title":"Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey","volume":"43","author":"Cornillet","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0630","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0635","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0640","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkq437","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients","volume":"66","author":"Pagano","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2018.01.002_bib0645","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005\u20132007)","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2018.01.002_bib0650","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0655","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.rmr.2018.01.002_bib0660","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/652768","article-title":"Factors associated with mortality in transplant patients with invasive aspergillosis","volume":"50","author":"Baddley","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0665","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-13-29","article-title":"Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes","volume":"13","author":"Baddley","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0670","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/cc3488","article-title":"Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome","volume":"9","author":"Garnacho-Montero","year":"2005","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.rmr.2018.01.002_bib0675","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.rmr.2018.01.002_bib0680","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0685","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3201\/eid1710.110226","article-title":"Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007\u20132009","volume":"17","author":"van der Linden","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0690","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/jac\/dks160","article-title":"High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR\/L98H, in a French cohort of patients with cystic fibrosis","volume":"67","author":"Morio","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2018.01.002_bib0695","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.mycmed.2015.06.018","article-title":"L\u2019\u00e9tude multicentrique prospective RADAR\u00a0: r\u00e9sultats pr\u00e9liminaires de l\u2019\u00e9valuation de la r\u00e9sistance aux azol\u00e9s des isolats d\u2019Aspergillus fumigatus de 12\u00a0centres hospitaliers fran\u00e7ais","volume":"25","author":"Murat","year":"2015","journal-title":"J Mycol Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib0705","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/CMR.00055-08","article-title":"Pathogenesis of Aspergillus fumigatus in invasive aspergillosis","volume":"22","author":"Dagenais","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.rmr.2018.01.002_bib0710","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/cid\/ciu337","article-title":"Immune correlates of protection in human invasive aspergillosis","volume":"59","author":"Camargo","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0715","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0720","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMra0808853","article-title":"Aspergillosis","volume":"360","author":"Segal","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib0725","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0730","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1016\/j.ejrad.2009.05.058","article-title":"Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: a useful tool for diagnosis and assessment of outcome in clinical trials","volume":"74","author":"Caillot","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0735","first-page":"242","article-title":"Pulmonary Aspergillosis: clinical presentation, diagnostic tests, management and complications","volume":"16","author":"Sherif","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib0740","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0745","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/cir122","article-title":"The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts","volume":"52","author":"Georgiadou","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0750","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1399-3062.2010.00499.x","article-title":"Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients","volume":"12","author":"Park","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0755","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1469-0691.2010.03301.x","article-title":"Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections","volume":"17","author":"Hot","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2018.01.002_bib0760","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2011-04-351601","article-title":"The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies","volume":"119","author":"Bergeron","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rmr.2018.01.002_bib0765","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/mmy\/myu064","article-title":"Identification of filamentous fungi isolates by MALDI-TOF mass spectrometry: clinical evaluation of an extended reference spectra library","volume":"52","author":"Becker","year":"2014","journal-title":"Med Mycol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0770","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1128\/JCM.00049-14","article-title":"Use of the Bruker MALDI Biotyper for identification of molds in the clinical mycology laboratory","volume":"52","author":"Schulthess","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0775","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1469-0691.12513","article-title":"Update on antifungal resistance in Aspergillus and Candida","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2018.01.002_bib0780","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3109\/13693786.2010.499916","article-title":"Aspergillus species intrinsically resistant to antifungal agents","volume":"49","author":"Van Der Linden","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0785","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fmicb.2016.00683","article-title":"Aspergillus fumigatus-related species in clinical practice","volume":"7","author":"Lamoth","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0790","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1128\/IAI.62.12.5424-5433.1994","article-title":"Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus","volume":"62","author":"Latg\u00e9","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.rmr.2018.01.002_bib0795","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1473-3099(04)01045-X","article-title":"Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis","volume":"4","author":"Mennink-Kersten","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0800","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1086\/343804","article-title":"Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients","volume":"186","author":"Maertens","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0805","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2011.178","article-title":"ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients","volume":"47","author":"Marchetti","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.rmr.2018.01.002_bib0810","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/mmy\/myv026","article-title":"The use of biomarkers and molecular methods for the earlier diagnosis of invasive aspergillosis in immunocompromised patients","volume":"53","author":"Ambasta","year":"2015","journal-title":"Med Mycol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0815","first-page":"CD007394","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromized patients","author":"Leeflang","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2018.01.002_bib0820","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0825","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1600-6143.2004.00415.x","article-title":"Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients","volume":"4","author":"Husain","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.rmr.2018.01.002_bib0830","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1128\/JCM.00506-08","article-title":"Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients","volume":"47","author":"Hachem","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0835","series-title":"Clinical mycology","first-page":"271","author":"Malcolm","year":"2009"},{"key":"10.1016\/j.rmr.2018.01.002_bib0840","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1128\/JCM.44.2.389-394.2006","article-title":"Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders","volume":"44","author":"Aubry","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0845","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJM200312113492424","article-title":"False-positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam","volume":"349","author":"Sulahian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib0850","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/JCM.42.10.4744-4748.2004","article-title":"Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction","volume":"42","author":"Walsh","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0855","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jinf.2015.02.012","article-title":"False-positive Aspergillus galactomannan and its kinetics in allogeneic hematopoietic stem cell transplantation","volume":"70","author":"Kimura","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.rmr.2018.01.002_bib0860","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1128\/JCM.00750-11","article-title":"Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients","volume":"50","author":"Bergeron","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0865","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1378\/chest.09-0701","article-title":"Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies","volume":"137","author":"Bergeron","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2018.01.002_bib0870","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1378\/chest.10-0488","article-title":"Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review","volume":"138","author":"Guo","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2018.01.002_bib0875","doi-asserted-by":"crossref","first-page":"e43347","DOI":"10.1371\/journal.pone.0043347","article-title":"Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis","volume":"7","author":"Zou","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.rmr.2018.01.002_bib0880","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/cc11443","article-title":"Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study","volume":"16","author":"He","year":"2012","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.rmr.2018.01.002_bib0885","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/647942","article-title":"Diagnostic performance of the (1 \u2192 3)-beta-D-glucan assay for invasive fungal disease","volume":"49","author":"Koo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0890","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1128\/JCM.03567-13","article-title":"Use and limits of (1-3)-\u03b2-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis","volume":"52","author":"Sulahian","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0895","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/cir897","article-title":"\u03b2-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3)","volume":"54","author":"Lamoth","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0900","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1111\/j.1469-0691.2012.03777.x","article-title":"Post-diagnostic kinetics of the (1 \u2192 3)-\u03b2-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia","volume":"18","author":"Koo","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2018.01.002_bib0905","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/JCM.02142-12","article-title":"Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillosis","volume":"51","author":"Wiederhold","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0910","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/myc.12343","article-title":"Diagnostic accuracy of the Aspergillus-specific bronchoalveolar lavage lateral-flow assay in haematological malignancy patients","volume":"58","author":"Prattes","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.rmr.2018.01.002_bib0915","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.201407-1275OC","article-title":"Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases","volume":"190","author":"Prattes","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib0920","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/JCM.01767-09","article-title":"Aspergillus PCR: one step closer to standardization","volume":"48","author":"White","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib0925","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/cid\/civ507","article-title":"Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing","volume":"61","author":"White","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0930","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.bbmt.2012.07.013","article-title":"Serum IgG responses against Aspergillus proteins before hematopoietic stem cell transplantation or chemotherapy identify patients who develop invasive aspergillosis","volume":"18","author":"Du","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.rmr.2018.01.002_bib0935","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1439-0507.2004.01035.x","article-title":"Antibody detection in patients with invasive aspergillosis","volume":"47","author":"Kappe","year":"2004","journal-title":"Mycoses"},{"key":"10.1016\/j.rmr.2018.01.002_bib0940","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.ijid.2009.07.011","article-title":"Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases","volume":"14","author":"Nam","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0945","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-125-3-199608010-00006","article-title":"Serodiagnosis and monitoring of Aspergillus infections after lung transplantation","volume":"125","author":"Tomee","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib0950","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/civ555","article-title":"Galactomannan and polymerase chain reaction-based screening for invasive Aspergillosis among high-risk hematology patients: a diagnostic meta-analysis","volume":"61","author":"Arvanitis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0955","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12879-015-0995-8","article-title":"Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia","volume":"15","author":"Paholcsek","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0960","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cmi.2015.09.009","article-title":"Prospective multicentre PCR-based Aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis","volume":"22","author":"Springer","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2018.01.002_bib0965","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0970","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.rmr.2018.01.002_bib0975","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib0980","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0985","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2018.01.002_bib0990","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib0995","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.rmr.2018.01.002_bib1000","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.rmr.2018.01.002_bib1010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1015","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/JCM.00863-13","article-title":"In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.01.002_bib1020","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.rmr.2018.01.002_bib1025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib1030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","author":"Singh","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.rmr.2018.01.002_bib1035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1040","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/0091270005281234","article-title":"Safety and pharmacokinetics of coadministered voriconazole and anidulafungin","volume":"45","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.rmr.2018.01.002_bib1045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/tid.12211","article-title":"Independent contribution of bronchoalveolar lavage and serum galactomannan in the diagnosis of invasive pulmonary aspergillosis","volume":"16","author":"Fisher","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1050","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1378\/chest.126.6.1783","article-title":"Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia","volume":"126","author":"Matt","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2018.01.002_bib1055","unstructured":"Pottecher B, Herbrecht R., Blanc-Vincent M.-P. FNCLCC 2000\u00a0SOR pour la pr\u00e9vention des infections nosocomiales en canc\u00e9rologie."},{"key":"10.1016\/j.rmr.2018.01.002_bib1060","series-title":"Conf\u00e9rence de consensus, pr\u00e9vention du risque aspergillaire chez les patients immunod\u00e9prim\u00e9s, (h\u00e9matologie, transplantation)","author":"ANAES-SFHH","year":"2000"},{"key":"10.1016\/j.rmr.2018.01.002_bib1065","article-title":"Quelles mesures pour ma\u00eetriser le risque infectieux chez les patients immunod\u00e9prim\u00e9s\u00a0? Recommandations formalis\u00e9es d\u2019experts","volume":"XXIV","author":"SF2H","year":"2016","journal-title":"Revue officielle de la Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne hospitali\u00e8re"},{"key":"10.1016\/j.rmr.2018.01.002_bib1070","series-title":"Risque infectieux fongique et travaux en \u00e9tablissements de sant\u00e9","author":"SF2H","year":"2011"},{"key":"10.1016\/j.rmr.2018.01.002_bib1075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib1080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.01.002_bib1085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rmr.2018.01.002_bib1090","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1128\/AAC.00581-15","article-title":"Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies","volume":"59","author":"Cumpston","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2018.01.002_bib1095","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/jac\/dkw079","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2018.01.002_bib1100","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/AAC.04035-14","article-title":"Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity","volume":"58","author":"Jung","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2018.01.002_bib1105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rmr.2018.01.002_bib1110","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1115","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1120","author":"Cornely","year":"2014"},{"key":"10.1016\/j.rmr.2018.01.002_bib1125","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rmr.2018.01.002_bib1130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs","volume":"34","author":"Wang","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1135","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/bjc.2012.147","article-title":"Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem cell transplantation: a systematic review and meta-analysis of randomised-controlled trials","volume":"106","author":"Ethier","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rmr.2018.01.002_bib1140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12879-015-0855-6","article-title":"Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"15","author":"Bow","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1145","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2006.01548.x","article-title":"Voriconazole prophylaxis in lung transplant recipients","volume":"6","author":"Husain","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.rmr.2018.01.002_bib1150","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3109\/00365548.2012.691207","article-title":"Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients","volume":"44","author":"Tofte","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.rmr.2018.01.002_bib1155","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","article-title":"Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation","volume":"29","author":"Monforte","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.rmr.2018.01.002_bib1160","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.05219-11","article-title":"Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity","volume":"56","author":"Mitsani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2018.01.002_bib1165","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation\u00a0\u2013\u00a0a world-wide survey","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.rmr.2018.01.002_bib0585","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1749-6632.2012.06829.x","article-title":"Risk stratification for invasive aspergillosis in immunocompromised patients","volume":"1272","author":"Herbrecht","year":"2012","journal-title":"Ann N Y Acad Sci"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842518300056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842518300056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T15:36:24Z","timestamp":1603899384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842518300056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0761842518300056"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2018.01.002","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspergillose pulmonaire invasive","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}